Key Trends in US Specialty Pharmacy and Access
Payer Perspectives and Developer Strategies, 2020-23

Isha Bangia  PhamD MBA, Manager, US Market Access, Certara (New Jersey)
Ulrich Neumann  FRSA, MBA, MSC MA, Senior Director & Head, US Access & Commercial Strategy, Certara (New York)

We would like to acknowledge the research of Maximilian Vargas, PhD MBA and thank both him, and Barbara Pannone, PhD for her instructive edits and feedback as well as Bill Weir for substantive copy review.
Corresponding author: Ulrich Neumann at Certara, 295 Madison Avenue, 23rd Floor, New York, NY 10017. Email: ulrich.neumann@certara.com
Report Overview

Welcome to the 2020 trends report.

To allow for the optimal positioning of your product, portfolio or company, it is critical to understand the various forces that shape the US specialty access landscape. For the last two decades, our team has been tracking a wide range of critical market access developments. Certara clients rely on tested playbooks to help them navigate complex and competitive situations such as:

- Increasing volume control over prescribed therapies by various payer types
- Tighter formularies and stricter utilization management
- Provider incentives shifting away from volume, physicians’ flexibility to make Rx decisions
- Increased patient exposure to out-of-pocket cost burden
- Consolidation in the site-of-care landscape and payer cost shifting strategies
- Rising complexity of reimbursement-relevant coding and billing procedures depending on setting/site of administration
- Growing payer ability to leverage biosimilar entrants and therapeutic alternatives across crowded drug classes

We usually look at how these forces shape the landscape for individual product or portfolio access. This report shares some of the broader and more ubiquitous market trends we have uncovered in our engagement with Certara’s ‘Compass Expert Panel’, a leading proprietary database of formulary decision makers in health plans, PBMs, hospitals/IDNs and channels influencing access, including specialty pharmacy, GPOs. Ready for rapid deployment, it is updated in real time and, to date, has been leveraged across hundreds of strategic projects in life sciences.

We are convinced that the range of topics discussed in this report will pique your interest and hopefully, encourage you to dig deeper. All of these are more than just trends. Successful developers need awareness of their individual context and strategic foresight in order to thrive in an environment that gets more complex every day. We are specifically including a section on future policies, some of which offer a drastic redesign of the current landscape described in the earlier chapters of the report. To enable decision-making in the face of ever more uncertainty, our consultants specialize in scientific value story development, pro-active policy and payer engagement, as well as multi-faceted go-to-market and distribution strategies.

Our team would be thrilled to schedule a personal consultation to discuss what these insights may mean for your product or pipeline asset. Please feel free to reach out.
Research Methodology

- Using Certara’s Compass research network, we conducted an online survey among active voting members of P&T committees in US managed care organizations (MCOs), followed by a set of semi-structured interviews for further interpretation and probing of key trends. In-depth interviews often help to clarify the gap between expressions in survey research and reality on the ground.
- A targeted literature review was conducted to contextualize the research in the current landscape of the specialty pharmacy category.
- Of 31 respondents, 19 were pharmacy directors and 12 were medical directors. These payers represent a total of 198.8M US lives (169.6M Commercial and 29.2M Medicare lives). All 31 respondents were responsible for Commercial lives and 25 of the 31 responsible for Medicare as well.
- Respondents were comprised of national (n=17) and regional health plans (n=14), pharmacy benefit managers (PBM; n=7) and integrated delivery networks (IDN; n=6).
- MCOs were also categorized by size, based on the number of covered lives, into large, mid-sized and small health plans
  - Small plans: <920,000 lives; n=7 plans
  - Mid-sized/medium plans: ≥920,000 lives and <3.4M lives) (n=8 plans)
  - Large plans: (≥3.4M lives) (n=11 plans)
- PBM: 59.5M lives (6 unique organizations)
- IDNs: 24.4M lives (6 unique organizations)
- Small plans: 3.4M lives (7 unique plans; includes PBM and IDN)
- Mid-sized/medium plans: 13.5M lives (8 unique plans; includes PBM and IDN)
- Large plans: 182M lives (11 unique plans; includes PBM and IDN).
- Parts of the analysis presented in this report have been accepted for publication as posters by the American Academy of Managed Care Pharmacy (AMCP) in 2020, one of which has been awarded a prestigious gold ribbon in professional review.1,2

Guidance on Document Use, Important Terms, and Abbreviations

LIST OF ABBREVIATIONS

| ACO | Accountable care organization |
| AMA | American Medical Association |
| AAFP | American Academy of Family Physicians |
| AMCP | Academy of Managed Care Pharmacy |
| CMS | Center for Medicare and Medicaid Services |
| ESI | Express Scripts |
| FDA | Food and Drug Administration |
| HHS | Department of Health and Human Services |
| ICER | Institute for Clinical and Economic Review |
| IDN | Integrated delivery network |
| MAPD | Medicare Advantage plan |
| MCO | Managed care organization |
| OBA | Outcomes-based agreements |
| OIG | Office of Inspector General |
| OMB | Office of Management and Budget |
| P&T | Pharmacy & Therapeutics |
| PA | Prior authorization |
| PBM | Pharmacy benefit manager |
| Rx | Prescription |
| SME | Small molecular entities |
| SPP | Specialty pharmacy provider |
| UM | Utilization management |
| US | United States |
| MAPD | Medicare Advantage plan |

Limitations

The estimates and findings in this report are based on a qualitative research methodology. Throughout this report, the numbers of covered Commercial and Medicare lives per health plan type are reported to illustrate and provide a deeper understanding of the research findings. The numbers of reported lives are approximations provided by research respondents.

Certara has not accounted for any overlap in covered lives between health plans. As such, findings on the trends we document should be considered indicative rather than conclusive.
The Shifting Landscape of Specialty Coverage
Market Context

- No universally accepted definition exists for specialty pharmaceuticals. Most refer to high-cost complex therapies often used for chronic conditions which require special monitoring, dose adjustments, special distribution and administration (self- or physician-administered injectables) practices.
- While larger, injectable, protein-based molecules (known as biologics) are most likely going to be specialty drugs, we note that roughly half of all specialty sales are still small molecular entities.\(^4\)
- Covering the range of $10,000 to $7,000,000 per patient annually, specialty drugs are understood to be higher priced therapies accounting for half of all US pharmaceutical spending roughly evenly split between the medical and the pharmacy benefit categories.\(^5,6\)
- The FDA has approved over 140 new specialty drugs since 2013 and approximately two-thirds of the 48 novel therapies approved in 2019 were specialty drugs.\(^7,8\) About 60% of new molecular entities awaiting FDA approval through 2021 can be classified as specialty pharmaceuticals\(^9\) as late stage pipelines are dominated by specialty therapies led by oncology indications and niche products across a range of classes.

Figure 1.
Pharmaceutical spending since 2015

Source: IQVIA, National Sales Perspectives, February 2020

\(^a\) $670 sponsor-negotiated price per Medicare standards for 2019\(^9\)
Market Context

- US specialty drug spending saw a modest annual growth of 3% from 44.7% in 2018 to 47.7% in 2019 per ESI. On the basis of non-discounted spending, specialty growth has been outpacing traditional product growth with a 10% to 0.3% dollar volume increase, per IQVIA.

- The two drivers of growing spending on specialty drugs are an increase in unit cost and increased utilization. Specialty utilization increased by 8% year-over-year (Y.O.Y) from 2017 to 2018.

- In 2018, the top ten specialty categories represented 87% of total specialty spend, with oncology, inflammatory diseases and multiple sclerosis as the leading categories. Prescription utilization across commercial plans for oncology and inflammatory conditions increased 4.4% and 3.6% and unit cost rose 13.7% and 10.5%, respectively. Notable drugs from these classes include Keytruda (pembrolizumab), Humira (adalimumab), and Enbrel (etanercept).

Figure 2.
Three therapy areas responsible for 2/3 of historic (5-year) sales growth and are dominating growth in recent (1-year) launches

Top-10 therapy area growth %

Bubble size = Total market size
Source: IQVIA, National Sales Perspectives, February 2020

- Specialty
- Traditional
- No growth
Key Market Trends

- Our survey confirms that inflammatory conditions, oncology and diabetes remain the top three categories of budgetary concern for Commercial and Medicare payers. They are responsible for two thirds of the absolute budgetary growth and dominate new launches. Budget impact is attributable to the combination of high priced therapies and a high number of patients in these categories.
- Payers are concerned that the growth of specialty drug costs is outpacing that of non-specialty drugs pointing to new approvals, strong research pipelines, limited competition and increased utilization among a growing number of patients.
- Our interviews confirmed the payer view that the slow introduction and uptake of biosimilars into the market has hindered potential cost savings. Payers express hope that over the next decade, biosimilar introductions could lead to costs savings in the range of $25B to $44B.15
- Payers mention that utilization surges can add the challenge of actuarial unpredictability since only about 5% of patients may account for half of a payer’s entire budget.
- Expanded indications, from original rare disease patient groups at launch to broader populations later on, make historic launch pricing untenable given considerable volume increases.

With respect to their management of the specialty category, the top 3 challenges noted by payers outside of rising cost are:

1. **The increased utilization and expanded indications of drugs** (cited by 15%)
   - It is estimated that 25-30M Americans live with a rare disease. 65% of new drug approvals in the next 3 years will fall into the rare disease and cancer categories, often for targeted therapies. In the aggregate, payers are concerned about the rising median cost per orphan drug patient.16

2. **A large number of rare disease products** (13%)
   - As of 2020, there are four gene therapies approved by the FDA with more than 900 INDs in clinical trials.17 The cumulative effect of curative therapies across multiple conditions is expected to put increasing strains on current ‘pay-as-you-go’ payment systems.
   - Collapsing decades worth of potential cost-offsets into the single, one-time administration of a drug produces extraordinary up-front budget pressures on payers.

3. **Entry of one-time treatments such as gene therapies** (12%)
   - Collapsing decades worth of potential cost-offsets into the single, one-time administration of a drug produces extraordinary up-front budget pressures on payers.

Figure 3.
Leading conditions of budget impact concern
With respect to their management of the specialty category, payers also see these top three opportunities:

**CHALLENGE 1** The increased utilization and expanded indications of drugs (cited by 15%)

- Traditionally, there has been little to no contracting for medical benefit products but that may be changing as systems evolve to incorporate pharmacy benefit strategies.
- As more clinically undifferentiated products (like biosimilars) enter a category, there are more opportunities to contract for preferred access.

**CHALLENGE 2** A large number of rare disease products (13%)

- Utilization management tactics remain the focal point for payers in managing spend in the specialty category and are expanding in most areas.
- Payers are determined to become more restrictive across the board with different tactics to contain costs.

**CHALLENGE 3** Entry of one-time treatments such as gene therapies (12%)

- Payers express a strong desire to manage the medical benefit like the pharmacy benefit and increasingly integrate coverage decisions across both categories. In shifting the medical benefit to parity with the pharmacy benefit, they hope to draw more heavily on UM tactics such as product exclusions and preferred products.
- No longer protected from cost containment, the medical benefit is now subject to the type of restrictions once limited to pharmacy benefit drugs. Payers reiterate that a key medical management objective is to move specialty infusions towards the lowest cost site of service.

Managed market success requires the tactical employment of a growing set of commercial partners. In today’s market, patient access and therapy use become a product of comprehensive employment of hubs, ‘wrap-around’ services, patient assistance and ‘quick-start’ programs. Interestingly, those are moving from specialty and orphan drugs to increasingly ‘hub’-lite areas like chronic care.

— PAUL GALLAGHER, Vice President, US Access Strategy, Certara

**Patient cost-sharing as leading response strategy**

- Payers listed “increased cost-sharing” as the leading strategy to finance specialty therapeutics across 50% of Commercial and 30% of Medicare lives overall.
- 42% of respondents have currently implemented cost-sharing for greater than 70% of covered Commercial lives. For the future, 67% of payers report they are likely to have implemented a cost-sharing strategy across Commercial lives.
- On the Medicare side, 35% of respondents have currently implemented cost-sharing for greater than 70% of covered lives. In the future, 48% are likely to use cost-sharing.
- Mid-sized plans (≥920,000 and <3.4M covered lives) draw on increased costsharing for 70-90% of Commercial lives while regional plans are nearly twice as likely as larger, national plans to expand it further. On the Medicare side, regional plans are four times more likely to utilize cost-sharing than national plans.

42% of respondents have currently implemented cost-sharing

---

* n=13; representing 49.7M Commercial lives  
* n=11; representing 3.2M Medicare lives  
* n=21 representing 107.4M Commercial lives  
* n=15, representing 9M Medicare lives
- Data from IQVIA shows that the growing shift towards higher deductibles and coinsurance (Figure 4) comes with tradeoffs as it can have a significant impact on patient’s medication compliance and drug waste. Patients generally show high sensitivity to higher out-of-pocket costs. As cost exposures are increased, the rate of prescription abandonment accelerates to over 60% at $250 monthly patient out of pocket costs.

![Figure 4. Rising patient cost share of deductibles and coinsurance (Commercial) Source: IQVIA Rx Benefit Design; IQVIA analysis](image)

![Figure 5. Increasing abandonment with level of patient cost exposure Source: IQVIA Formulary Impact Analyzer; IQVIA Analysis, Dec 2018](image)

**Case Example**

Hemophilia has traditionally been an indication with treatments managed under the medical benefit; however, as the category expands, new options have entered such as self-administered Hemlibra. A client approached Certara to better understand utilization management around hemophilia treatments and what restrictions are in place for these products. Certara conducted qualitative research to validate the hypothesis that payers have started to implement utilization management criteria seen with pharmacy benefit drugs in indications with drugs predominantly covered under the medical benefit, like hemophilia. Among national and regional payers and PBMs, Certara confirmed that most treatments across all four hemophilia indications are covered with a PA to the FDA-label or PA beyond the label tied to clinical trial design. The restrictions in this setting mimic those traditionally seen in categories managed under the pharmacy benefit. As Certara hypothesized, payers are becoming more stringent in the management of indications with largely infusible drugs, like hemophilia, in an attempt to manage high costs.
Utilization Management Restrictions
KEY TRENDS WITH RESPECT TO UTILIZATION MANAGEMENT (UM) REACH ACROSS EIGHT AREAS

**Trend 1** Prior authorizations limiting to populations narrower than label approved indication

**Trend 5** Split-fill program

**Trend 2** Reauthorization criteria based on improved clinical response to drug

**Trend 6** Evidence-based pathways promoted to specify drug use

**Trend 3** Designate preferred medical benefit specialty products

**Trend 7** Quantity restrictions

**Trend 4** Medical benefit products excluded

**Trend 8** “Brand A before Brand B” step edits expanded

### Average level of utilization management among payers, ranked by level of current implementation

<table>
<thead>
<tr>
<th></th>
<th>Commercial</th>
<th>Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantity restrictions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Brand A before Brand B” step edits in specialty categories</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reauthorization criteria based on improved clinical response to drug</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Split-fill program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Designate preferred medical benefit specialty products</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PA limit to populations narrower than FDA-approved indication based on clinical study design</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Implement evidence-based pathways that specify which drugs to use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exclude particular medical benefit products</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 6.
Average level of UM tactics in 2020, as estimated by Commercial and Medicare payers
Prior authorizations and reauthorizations

- Payers limit drug utilization to populations narrower than the FDA approved indication based on clinical study design. Restrictions beyond the FDA label make the PA process more rigorous and limit use of specialty medications.
- Payers require confirmation of clinical response to drug as renewal criteria. These reauthorization criteria are used by payers to ensure that continued use of a product is warranted. Evidence of clinical response to treatments is often required at annual or six-month intervals.

Current State

- 55% of surveyed payers utilize PAs beyond the label for an estimated 70% or more of their Commercial and Medicare lives.
- 70% of payers from PBM and 50% of IDN implement PAs beyond the label for at least 70% covered Commercial lives.
- According to the Kaiser Family Foundation, 72% of beneficiaries with Medicare Advantage require a prior authorization for Part B drugs. We find that 35% of payers are implementing a narrow PA for 70% (or more) Medicare lives.
- Two-thirds of payers utilize reauthorization criteria based on improved clinical response to drug for at least 70% of Commercial lives including 86% of PBMs, 80% of small and mid-sized plans, 66% of IDNs, and 56% of larger MCO plans.

Figure 7. Customary steps in the prior authorization

\[ g \text{ n}=17, \text{ representing } 34.3M \text{ Commercial lives} \]
\[ h \text{ n}=5, \text{ representing } 24.8M \text{ Commercial lives} \]
\[ i \text{ n}=3, \text{ representing } 1.1M \text{ Commercial lives} \]
\[ j \text{ n}=21, \text{ representing } 145.4M \text{ Commercial lives} \]
\[ k \text{ n}=7, \text{ representing } 57.3M \text{ Commercial lives} \]
\[ l \text{ n}=15, \text{ representing } 10.9M \text{ Commercial lives} \]
\[ m \text{ n}=6, \text{ representing } 5.1M \text{ Commercial lives} \]
\[ n \text{ n}=9, \text{ representing } 135.5M \text{ Commercial lives} \]
FUTURE EXPECTATION

- All commercial payers plan to expand the use of more stringent PA criteria for specialty medications. All PBM respondents and nearly eight in ten IDNs are likely to expand implementation of narrow PA in the future.

- We should note that US payers understand this to be a response mechanism, not a fait accompli. They use more stringent PA criteria in reaction to a certain pricing level. Certara’s price testing research routinely probes for price points at which payers are open to remove additional restrictions.

- 80% of smaller and mid-sized plans\(^o\) are more likely to embrace this approach than are large payers.

- Based on survey results, payers are expected to maintain status quo on the Medicare side, not aiming to expand PA beyond the label.

---

**Figure 8.**
PA to populations narrower than the FDA approved indication

**Figure 9.**
Reauthorization criteria based on improved clinical response to drug

---

\(o\) n=12, representing 11.6M Commercial lives
• There will be a 62% increase in the number of payers using reauthorization criteria for Medicare lives, up from 42% to 68% of payers.
• Nearly 9 in 10 commercial payers are likely to expand future use of reauthorization criteria as a means for cost containment.
• While PAs and reauthorizations are seen as an effective means for cost containment and reduction of drug waste from the payer perspective, they do increase the treatment burden for patients, providers and developers from an access perspective.

Provider burden

• According to the American Medical Association (AMA), 9 in 10 physicians find that prior authorizations have a negative impact on patient outcomes and believe the burden associated with PAs has increased over the past 5 years.²³ 79% of physicians report that they sometimes, often or always have to submit medication reauthorizations when a patient with a chronic condition is stabilized.²⁴
• Most of Certara’s physician research engagements are aimed to give a nuanced perspective on the level of disruption or burden of the administrative procedure that is associated with PA. It depends on various factors such as provider type, indication, type (e.g. soft, or requiring lab values etc.) and associated requirements (e.g. step edits).

"The prior authorization process is out of control. It is increasing and rather than a tool for preventing unnecessary or expensive care, prior authorizations negatively impact my patients’ health and is a significant cause for family physician burnout and the closure of small private practices."

– DR. JOHN CULLEN
American Academy of Family Physicians (AAFP)²²

Patient burden

• Nearly 8 in 10 physicians find that PAs may result in patients stopping treatment and sometimes lead to treatment abandonment.²³
• 9 in 10 physicians report that PAs cause delays in patient care.²⁶,²⁷
• PAs also impact therapeutic areas with recognized need of treatment personalization. According to a survey among cancer radiologists, 73% report their cancer patients regularly express concern about the delay caused by prior authorizations, forcing a third of doctors to pursue different treatments than the ones indicated just to avoid such delays.²⁸

The prior authorization process is out of control. It is increasing and rather than a tool for preventing unnecessary or expensive care, prior authorizations negatively impact my patients’ health and is a significant cause for family physician burnout and the closure of small private practices.

– DR. JOHN CULLEN
American Academy of Family Physicians (AAFP)²²

23% OF SURVEY RESPONDENTS FIND MORE AGGRESSIVE UM AN OPPORTUNITY IN MANAGING THE SPECIALTY CATEGORY

Opportunities in specialty category

Additional contracting opportunities
More aggressive UM
Encourage biosimilar and generic utilization
More restrictive benefit designs
Changes to physician drug reimbursement
Stakeholder education
Other

Figure 10.
Payer noted opportunities in the specialty category
When beneficiaries and providers appealed preauthorization and payment denials, Medicare Advantage Organizations (MAOs) overturned 75 percent of their own denials during 2014–16, overturning approximately 216,000 denials each year. During the same period, independent reviewers at higher levels of the appeals process overturned additional denials in favor of beneficiaries and providers. The high number of overturned denials raises concerns that some Medicare Advantage beneficiaries and providers were initially denied services and payments that should have been provided. This is especially concerning because beneficiaries and providers rarely used the appeals process, which is designed to ensure access to care and payment. During 2014-16, beneficiaries and providers appealed only 1 percent of denials to the first level of appeal.

“...

– HHS OFFICE OF THE INSPECTOR GENERAL, 2018 American Academy of Family Physicians
Restrictive prior authorization practices can cause unnecessary, stressful and potentially life-threatening delays for cancer patients. ... In its current form, prior authorization causes immense anxiety and wastes precious time for cancer patients.

— PROF. PAUL HARARI, MD, FASTRO
Chairman of Human Oncology, University of Wisconsin-Madison

Case Example

- A manufacturer in early Phase 3 planning to launch a second-to-market product for a rare disease wanted to assess the current level of management and access in the category.
- Certara conducted MCO payer interviews covering a total of 73M lives. Almost ¾ of commercial payers were managing the category with a prior authorization going beyond the FDA label. Payers anticipated similar coverage for new category entrants and criteria beyond the label most often aligned with clinical trial criteria. Certara, together with the commercial team, engaged the clinical team to clarify how the clinical trial design would impact access, and, as a result, commercial forecasts and product revenue, if based on a broad indication.
- In such instances, tighter integration across manufacturers between clinical and commercial teams especially at earlier stages, is warranted. Incorporating payer feedback early in the development process can align commercial forecasts with clinical development to ensure maximized revenue and access.

Figure 12.
Prior authorization criteria for a rare disease product
Designating Preferred Specialty Products on the Medical Benefit

- Compared to treatments on the medical benefit, medications covered on the pharmacy benefit traditionally allow payers to have more control on management and utilization.
- Specialty drugs covered on the medical benefit (physician administered) are no longer immune to UM tactics such as product exclusions and designated preferred products as payers try to integrate medical and pharmacy benefits.
- According to Express Scripts data, up to 15% of the specialty spend could be reduced by health plans implementing medical benefit management services.31

CURRENT STATE
- All surveyed IDNs currently implement preferred medical products for 70% or more lives.
- One in two MCO plans, regardless of plan size, implements this UM tactic for medical benefit drugs.

FUTURE EXPECTATION
- Going forward all payers will likely expand, or in the case of IDNs continue, this model of preferred medical treatments.
- Based on the status quo, we may see more preferred products on PBM and MCO formularies in the coming years.

Figure 13. Total specialty spend between benefit type

US health plan sponsors are projected to waste more than $9 billion, or 49% of their total pharmacy spend on specialty medication services that provide no additional value. This wasteful spending could be recovered if payers applied the same cost-saving techniques from the pharmacy benefit on medications that are administered through the medical benefit.

– BRIAN SEIZ PharmD, President Pharmacy at Express Scripts

Figure 14. Designating preferred specialty products

PREFERRED SPECIALTY PRODUCTS ON MEDICAL BENEFIT

<table>
<thead>
<tr>
<th>CURRENT LEVEL OF IMPLEMENTATION</th>
<th>FUTURE LIKELIHOOD FOR EXPANSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not at all likely</td>
<td>Highly likely</td>
</tr>
<tr>
<td>Not implemented</td>
<td>Medicare</td>
</tr>
<tr>
<td>Limited rollout &lt;15% of lives</td>
<td>Commercial</td>
</tr>
<tr>
<td>Implemented for &gt;50% of lives</td>
<td>Medicare</td>
</tr>
<tr>
<td>Implemented for &gt;75% of lives</td>
<td>Commercial</td>
</tr>
<tr>
<td>Fully implemented, &gt;90% of lives</td>
<td>Medicare</td>
</tr>
</tbody>
</table>

n=6, representing 18.6M Commercial lives  n=18

n=18

n=6, representing 18.6M Commercial lives

n=18
Increasing Product Exclusions of Specialty Drugs

- The concept of product exclusions traditionally applied to small-molecule drugs on the pharmacy benefit.
- Payers started introducing product exclusion lists as another UM tool and cost containment strategy. While traditional drug classes see this more than specialty drugs, specialty drugs in rare diseases and on the medical benefit are no longer immune to exclusions.
- The first exclusion list, released by CVS in 2012, only applied to small-molecule non-specialty drugs. In 2017, CVS also began excluding products for rare diseases such as Gleevec and Tasigna for chronic myeloid leukemia (CML), though still on the pharmacy benefit.33,34
- In 2014, ESI started excluding certain specialty products like biologics Cimzia, Simponi, Stelara, Xeljanz for inflammatory indications.35 In 2019, 50 new drugs were excluded including specialty products like Onpattro for polyneuropathy of hereditary transthyretin-mediated amyloidosis. In 2020, ESI is excluding 32 new drugs from its national formulary including specialty products like Factor VIII recombinant products for hemophilia and granulocyte stimulating agents.36
- Other important payers such as Cigna, Aetna, Optum, and Prime Therapeutics also began product exclusions since 2016.37

CURRENT STATE
- We find that there is still overall limited implementation of product exclusions across all payers today with only a quarter of payers’ excluding particular specialty products covered on the medical benefit 70% or greater covered Commercial lives.
- 12% of survey respondents consider more restrictive benefit designs a key opportunity in managing specialty pharmaceuticals.

FUTURE EXPECTATION
- All payer archetypes anticipate to expand use of this tactic to more covered Commercial lives in the next few years with more than two-thirds of the 31 payer respondents likely to begin excluding particular medical benefit products.

Number of brand exclusions from PBM formularies


Figure 15.

<table>
<thead>
<tr>
<th>Year</th>
<th>Express Scripts</th>
<th>CVS Caremark</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>58</td>
<td>0</td>
</tr>
<tr>
<td>2013</td>
<td>50</td>
<td>0</td>
</tr>
<tr>
<td>2014</td>
<td>48</td>
<td>0</td>
</tr>
<tr>
<td>2015</td>
<td>66</td>
<td>0</td>
</tr>
<tr>
<td>2016</td>
<td>95</td>
<td>124</td>
</tr>
<tr>
<td>2017</td>
<td>87</td>
<td>154</td>
</tr>
<tr>
<td>2018</td>
<td>85</td>
<td>154</td>
</tr>
<tr>
<td>2019</td>
<td>242</td>
<td>175</td>
</tr>
</tbody>
</table>

Figure 16.
Exclude particular medical benefit products
Split-fill Programs

- Split-fill (also known as partial fill) programs for oral medications allow payers to reduce medication waste, improve medication adherence and consequently drive down costs.

CURRENT STATE

- AllianceRx Walgreens Prime research found that within the first 3 months of implementing a split-fill program, payers would see savings of $2,724 per month on average for one oral oncology medication. Within the first month, split-fill was associated with a $132.50 lower copay than non-split fills (p<0.007).  
- Split-fill programs showed lower discontinuation rates, pharmacy costs and potential wastage as demonstrated by a study of an oral oncology split fill program in a national specialty pharmacy. Within six months, the Walgreens program saved $2,646.74 monthly in medication wastage.
- Only about 30% of all payers have not implemented any split-fill programs for specialty products within their organizations--half of them PBM and IDN payers.

Figure 17.
Monthly mean differences in cost between split-fill and nonsplit-fill

<table>
<thead>
<tr>
<th>Month filled</th>
<th>AWP $*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3,118.90</td>
</tr>
<tr>
<td>2</td>
<td>2,259.80</td>
</tr>
<tr>
<td>3</td>
<td>2,796.20</td>
</tr>
<tr>
<td>3-month average</td>
<td>2,714.97</td>
</tr>
</tbody>
</table>

Figure 18.
Split-fill Programs

<table>
<thead>
<tr>
<th>CURRENT LEVEL OF IMPLEMENTATION</th>
<th>FUTURE LIKELIHOOD FOR EXPANSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not implemented</td>
<td>Average all payers</td>
</tr>
<tr>
<td>Limited rollout &lt;30% of lives</td>
<td>PBM</td>
</tr>
<tr>
<td>Implemented for 30% of lives</td>
<td>Large plans</td>
</tr>
<tr>
<td>Implemented for 50% of lives</td>
<td>Mid-sized plans</td>
</tr>
<tr>
<td>Implemented for 70% of lives</td>
<td>Small plans</td>
</tr>
<tr>
<td>Fully implemented, &gt;90% of lives</td>
<td>IDNs</td>
</tr>
</tbody>
</table>

1 n=10, representing 48.8M Commercial lives
FUTURE STATE

• In the future, the utilization of split-fills is likely to remain relatively stagnant with 75% of payers continuing use. Oncology, inflammatory conditions and MS are the top indications in which payers implement split-fills, though split-fill is present in other indications like diabetes, asthma and hypercholesterolemia.

<table>
<thead>
<tr>
<th>Categories with split-fill programs</th>
<th>Number of mentions (total=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>17</td>
</tr>
<tr>
<td>Inflammatory conditions</td>
<td>5</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>5</td>
</tr>
<tr>
<td>High cholesterol</td>
<td>2</td>
</tr>
<tr>
<td>Attention deficit disorders</td>
<td>1</td>
</tr>
</tbody>
</table>

Figure 19.

Indications with most split-fill use

“
We continue to expand the number of medications available under our split-fill program to support patients and maximize the investments health plans make in their patients.

— RICK MILLER
VP, Clinical and Professional Services AllianceRx Walgreens Prime

"
Evidence-based Pathways: Increased use to Manage Specialty Drugs

- Treatment guidelines like the National Comprehensive Cancer Network (NCCN) and supporting literature have been used by payers to provide evidence-based care.
- Payers are able to standardize care and maintain indication costs by covering specific products recommended per evidence-based pathways.
- In 2019, ESI estimated that $1.3B could be saved annually in specialty costs by implementing evidence-based UM policies for medical benefit drugs similar to those done for the pharmacy benefit.\(^{41}\)
- ESI reports that 15-20% of current drug claims do not follow treatment guidelines.\(^{42}\)

**Figure 20.**
Level of implementation of evidence-based pathways for drug use
• In our analysis, PBMs and IDNs see the highest level of implementation of evidence-based pathways, as well as the highest expressed interest to expand them further.

• Rheumatology, cardiology, diabetes and MS are found to have the most uptake of evidence-based pathways outside of oncology. Clinical guidelines and randomized controlled trials are the most common sources for evidence-pathway development (Figure 21).

Figure 21.

Top sources of data for development of evidence-based pathways

FUTURE EXPECTATION

• 60% of payers of which half are large health plans, are likely to implement evidence-based pathways that specify which drugs to use in the near future; this is an almost 4-fold increase from the status quo of payers fully utilizing evidence-based pathways for Commercial lives. As larger plans are more likely to adopt evidence-based pathways, smaller and mid-sized plans may follow suit.

• We find that the expected increase in providing evidence-based care will come largely from IDNs and MCOs as opposed to PBMs.

• Certara research indicates that oncology, diabetes, and MS are key therapeutic areas where payers rely on evidenced-based pathways in formulary decision-making processes.

• In oncology, a pathway is typically developed for first-line treatments and not later lines. Payers develop these pathways to specify which drugs should be used first and while physicians are not required to follow the guidance, they are incented to do so, usually by a monetary incentive.
Quantity Restrictions and Step Edits

- Quantity limits and step edits have been cited as two of the most common restrictions payers use in drug management.44
- Our research confirms that quantity restrictions and step edits are the most implemented UM tactics with the latter seeing further expansion across all payer types in the future.

**Figure 22. Current and future utilization of quantity limits**

<table>
<thead>
<tr>
<th>QUANTITY RESTRICTIONS</th>
<th>FUTURE LIKELIHOOD FOR EXPANSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>CURRENT LEVEL OF IMPLEMENTATION</td>
<td></td>
</tr>
<tr>
<td>Not implemented</td>
<td>Limited rollout &lt;10% of lives</td>
</tr>
<tr>
<td>Average all payers</td>
<td>PBM</td>
</tr>
<tr>
<td>Not at all likely</td>
<td>Unlikely</td>
</tr>
</tbody>
</table>

**Figure 23. Current and future utilization of Brand A before B step edits**

<table>
<thead>
<tr>
<th>STEP EDITS</th>
<th>FUTURE LIKELIHOOD FOR EXPANSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>CURRENT LEVEL OF IMPLEMENTATION</td>
<td></td>
</tr>
<tr>
<td>Not implemented</td>
<td>Limited rollout &lt;10% of lives</td>
</tr>
<tr>
<td>Average all payers</td>
<td>PBM</td>
</tr>
<tr>
<td>Not at all likely</td>
<td>Unlikely</td>
</tr>
</tbody>
</table>

 商業 | 医療保険
DEVELOPER TAKEAWAYS

• Clinical trial designs are subject to scrutiny as a means to limit product use with a narrower PA than the FDA label.
• Developers of specialty pharmaceuticals will be subject to more stringent reauthorization criteria which will likely align with clinical response.
• Strong engagement with payers via advisory board and primary research provides vital insight on PA management and criteria that may be included in PAs.
• Developers must be proactive with payer engagement to understand the current reauthorization environment for their product’s respective indication and competition.
• Developers should educate payers on clinical endpoints/responses that are most relevant for their product.
• A robust assessment of clinical trial designs through the payer perspective early on in the clinical development phases is warranted to ensure the most appropriate and widest patient inclusion criteria are developed.
• An expanded use of product exclusions by payers suggests that payers are unable to distinguish value across products in crowded therapeutic areas.
• Payers may use product exclusions to negotiate deeper rebates with developers.
• Developers must leverage attributes of product value that may warrant a preferred product status outside of and beyond price.
• Key considerations for developers include:
  • Will inclusion in certain guidelines or treatment protocols such as the NCCN allow for better access at the payer level?
  • Does the timing of inclusion vs. P&T review impact access?
  • Does use of evidence-based pathways vary across payer segments?
  • What can developers do to support physician use of evidence-based pathways?

“The definition of what constitutes “value” for healthcare interventions is an incredibly complex and hotly debated topic. However, regardless of the school of thought you come from, there is broad consensus that value assessment must take into consideration a multitude of factors beyond purely economic ones. Especially important in value assessment are factors such as unmet needs and disease severity, in particular this applies for rare diseases. Whether they are explicitly or implicitly captured in the assessment criteria, it is clear that healthcare decision-makers are indeed swayed by these factors, and as such it is critical for developers take a holistic approach to their evidence development and communication activities.

— ROMAN CASCIANO
General Manager and SVP, Certara Evidence & Access
A manufacturer in a specialty category needed to test the brand messaging and determinants of value for its flagship product. Certara conducted an evidence based assessment of the product’s value story with 15 MCOs and GPO. Certara was able to identify key clinical and class elements important to payers which were likely to result in perceived meaningful differentiation.

Figure 24.
Payer assessment of key elements of product value

A developer in the oncology space wanted to understand the impact inclusion in the NCCN guidelines has on formulary coverage when the FDA label is narrow. The developer was anticipating a narrow FDA label but inclusion in the NCCN guidelines for a broader indication. Certara’s initial hypothesis was that in oncology, payers rely heavily on evidence-based pathways to guide formulary decisions. Through discussions with our proprietary payer network, Certara assessed the extent to which national and regional MCO payers align formulary coverage with NCCN guidelines and FDA labels. Certara was able to validate that a majority of payers will align coverage with broader NCCN guidelines over the FDA label for product use. Certara advised the manufacturer to develop a strong key opinion leader (KOL) education and engagement strategy as an initial step to be positioned in clinical guidelines. We recommended that the developer conduct an advisory board to facilitate KOL engagement around product value.

Figure 25.
Evidence-based pathways impact on access
Distribution Channels
Disruption
Increase in Limited Distribution for Specialty Pharmaceuticals

- Payers’ preferred distribution channel for pharmacy benefit specialty medications are specialty pharmacies through a limited distribution network, which are owned today by various market entities. Approximately 80% of payers required certain specialty drugs to be dispensed through specialty pharmacies in 2018.45

- Limited distribution networks can limit medication access for providers as HCPs and hospitals not part of a limited network may have to pay higher costs to obtain drugs.

Shifting away from ‘buy-and-bill’ on the medical benefit

- Specialty drugs are reimbursed through the supply chain as either a pharmacy benefit, or as a medical benefit, through the buy-and-bill model. Each channel receives different reimbursement and is subject to different management practices.

- Similar to utilization management, distribution on the pharmacy benefit allows payers to have more control and management over medication use as compared to buy-and-bill practices on the medical benefit. Payers leverage specialty pharmacies to provide cost management and coordinated patient care leading to better health outcomes.

Figure 26.
Flow of buy-and-bill distribution
CURRENT STATE

• Today only about 30% of PBM respondents have fully implemented mandated use of specialty pharmacy, and/or direct contracting to eliminate buy-and-bill across Commercial lives whereas 80% of IDNs have done so.

• 42% of large, mid-sized and small health plans have specialty pharmacy use and/or direct contracting implemented for 70%+ of Commercial lives.

FUTURE EXPECTATION

• Research shows an upwards trend in the mandated use of specialty pharmacy from payers. More than 75% of payers, including MCOs, IDNs and PBMs are likely to expand use of specialty pharmacy within the next three years.

• On the medical benefit side, the key trend being seen is an overall push away from the traditional buy-and-bill practices towards alternative distribution strategies that allow payers to have more control over drug use such as payers taking over distribution themselves.

• Across our survey respondents, about two-thirds have not increased physician reimbursement for lower cost options among specialty buy-and-bill products.

DISRUPTORS ON OUR RADAR

• High-cost, curative therapies bring significant challenges to the traditional buy-and-bill reimbursement model. As more one-time treatments like gene therapies enter the market, novel distribution alternatives are emerging.

• The 2020 initiative “Embarc Benefit Protection” establishes Cigna as an in-network gene therapy provider. Employers and plan sponsors will pay a $12 per-member monthly fee for access to Luxturna and Zolgensma with a zero OOP. Eventually, Cigna plans to include more gene therapies like CAR-Ts, into the program.

• Through previous vertical integration and expansion, Cigna owns a specialty pharmacy network (Accredo), specialty pharmacy distributors (CursaScriptSD, ESI), a medical benefits management company (eviCore) and a PBM (ESI). Cigna can use this armamentarium to be an in-network gene therapy provider. The Embarc program increases Cigna’s position as it will serve as payer and distributor, the first time we have seen this level in a high-cost area.46,47

Payers that participate with us will be getting the best price. They will be getting uniform utilization management.

STEVE MILLER, MD, Chief Clinical Officer, Cigna

– STEVE MILLER, MD, Chief Clinical Officer, Cigna
Amazon: PillPack

• Amazon’s acquisition of PillPack, the online pharmacy, is an enormous advance for the retailer within the drug distribution channel. PillPack brings economies of scale to the medication supply chain by coordinating, organizing, packaging and supplying presorted doses of medications directly to millions of patients.

• While still unclear how PillPack will play in the specialty category, PillPack could limit distribution through PBM-owned specialty pharmacies and provide an alternative avenue of distribution that developers and health plans directly contract or integrate with PillPack’s ecommerce model which can decrease the practice of polypharmacy.48

“BCBS of Massachusetts has partnered with PillPack to integrate their pharmacy services into BCBS’s website and app concluding that “Members have reported higher satisfaction with PillPack than with other pharmacy options”.49

DEVELOPER TAKEAWAYS

• The shift away from buy-and-bill on the medical benefit side means that health plans are contracting more directly with developers as a means to achieve deeper discounts on products and avoid markups from provider facilities.50

• Payers are taking on more distributor roles. The shift to alternative strategies such as direct contracting and clearbagging spurs payers’ more pro-active distribution management.51

• Consider direct purchasing such as when Harvard Pilgrim contracted directly to receive Luxturna from Spark Therapeutics rather than hospitals purchasing the product. Harvard Pilgrim supplies Luxturna to its contracted treatment centers, but it can avoid any additional markups hospitals would have added to Luxturna.52

• In such instances, payers can verify coverage before a drug is shipped/dispensed to patients, allowing for more management of utilization. Such a proactive approach allows payers to have similar influence in managing the medical benefit as they do pharmacy benefit. However, hospital purchasers (pharmacy directors) in Certara research have voiced their frustration with mandated buys from specialty pharmacies, leading many to open up their own specialty pharmacy, or in some instances push back to request buy-and-bill.

• As utilization moves away from buy and bill, patients may experience greater cost sharing as the product is now paid out of their pharmacy benefit, providers may experience benefits related to inventory management and challenges related to reductions in revenue and additional access controls. Manufacturers may experience additional controls on utilization as authorization becomes even more proactive.
Rising Cost Effectiveness Considerations
Figure 28.

Payer readiness to employ ICER in P&T

We are integrating ICER assessments directly into the formulary evaluation process of our P&T committee. It has helped us improve the quality of our value assessments.

**REGIONAL PLAN**

We used the ICER report in our negotiations. Did we receive the ICER price? The answer is no, we didn’t.

**NATIONAL PBM**

It will be necessary to include new bases of clinical and financial review... such as comparative effectiveness and QALYs, as the drugs are too expensive to pay for if they don’t deliver enough either to individuals or populations.

**NATIONAL PBM**

People are finding the QALY concept to be more and more acceptable. As these kinds of approaches get adapted... pharma will have to change its view on what best pricing is.

**NATIONAL PBM**

I think everyone would welcome, including pharma and payers, a value-based pricing mechanism ... In the UK, they have NICE and in the United States we have ICER.

**REGIONAL PLAN**

I don’t know what the right threshold is. But the fact that there is no agreement doesn’t mean that the threshold is unlimited. The Brits actually get this, while we pretend it’s an unlimited budget.

**REGIONAL PLAN**

Information from ICER on complex disease states has been helpful... using their report saves us roughly $10-30k per P&T meeting.

**REGIONAL PLAN**

ICER is responding to real needs in the marketplace, which is why it has become so visible.

**IDN**

...an important component to drug coverage decisions, helping to ensure the most clinically appropriate and cost-effective medications are preferred in drug formulary.

**NATIONAL PBM**
The public debate around drug pricing has spurred demand for standardized value assessment in the US. A venture-funded think-tank called “ICER” (Institute for Clinical and Economic Review), has made its name as America’s “drug price watchdog”, selecting pharmaceutical products for review under cost effectiveness criteria. The incremental health gains are measured in quality adjusted life years and equal value of life years gained, as complimentary method the organization suggests for life extending treatments (Figure 29).

97% of reports the organization published online in 2018 found that developer WAC prices do not match the value the products provide, requesting discounts beyond 60% in nearly half of all reviews. To further address affordability concerns, “ICER” also projects a budget impact of interventions on the basis of a population-level back of the envelope calculation for the US healthcare system as shown in (Figure 30).

### The ICER framework

- Long-term value for money
- Comparative clinical effectiveness
- Incremental cost-effectiveness
- Other benefits or disadvantages
- Contextual considerations

### Table 1: Assumptions, ICER budget impact calculation

<table>
<thead>
<tr>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth in US GDP +1%</td>
</tr>
<tr>
<td>Total personal medical care spending, 2018 estimate</td>
</tr>
<tr>
<td>Contribution of drug spending to total health care spending (%) (Row 4 + Row 2)</td>
</tr>
<tr>
<td>Contribution of drug spending to total health care spending, 2018</td>
</tr>
<tr>
<td>Annual threshold for net health care cost growth for ALL drugs (Row 1 x Row 4)</td>
</tr>
<tr>
<td>Average annual number of new molecular entity approvals over 5 years (2014-2018)</td>
</tr>
<tr>
<td>Annual threshold for average cost growth per individual new molecular entity (Row 5 + Row 6)</td>
</tr>
<tr>
<td>Annual threshold for estimated potential budget impact for each individual new molecular entity (doubling of Row 7)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Estimate</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth in US GDP +1%</td>
<td>3.5%</td>
<td>World Bank, 2019</td>
</tr>
<tr>
<td>Total personal medical care spending, 2018 estimate</td>
<td>$2.95 Trillion</td>
<td>CMS National Health Expenditures, 2019</td>
</tr>
<tr>
<td>Contribution of drug spending to total health care spending (%) (Row 4 + Row 2)</td>
<td>16.9%</td>
<td>Calculation</td>
</tr>
<tr>
<td>Contribution of drug spending to total health care spending, 2018</td>
<td>$498.6 Billion</td>
<td>CMS National Health Expenditures, 2019; Altarum Institute, 2018</td>
</tr>
<tr>
<td>Annual threshold for net health care cost growth for ALL drugs (Row 1 x Row 4)</td>
<td>$17.4 Billion</td>
<td>Calculation</td>
</tr>
<tr>
<td>Average annual number of new molecular entity approvals over 5 years (2014-2018)</td>
<td>42.6</td>
<td>FDA, 2019</td>
</tr>
<tr>
<td>Annual threshold for average cost growth per individual new molecular entity (Row 5 + Row 6)</td>
<td>$409.6 Million</td>
<td>Calculation</td>
</tr>
<tr>
<td>Annual threshold for estimated potential budget impact for each individual new molecular entity (doubling of Row 7)</td>
<td>$819 Million</td>
<td>Calculation</td>
</tr>
</tbody>
</table>

### Figure 29.
(Simplified) components of ICER’s value framework and cost-effectiveness calculation

### Figure 30.
Assumptions, ICER budget impact calculation
Source: ICER
Public payer statements (as shown in figure 28) for a broader adoption of value-based pricing and numerous recent research surveys have shown the growing desire to see the appraisal of pharmaceuticals based on QALYs. Some recent surveys indicate that 9 out of 10 payers would see a need for a US HTA, with 64.5% saying they are ‘likely’ and ‘extremely likely’ to follow ICER’s cost-effectiveness discussion.

In contrast, we see very limited use of QALY-based, cost-effective analyses today among the surveyed payers for this research. The approach is reported to guide formulary inclusion/exclusion with an estimated implementation of less than 10% of Commercial and Medicare lives. Clinical comparative effectiveness analyses see a higher level of implementation in about 40% of Commercial lives. Too often ICER reports do not get published in time for the initial P&T committee discussion.

Follow-up interviews with our experts reveal that from an actuarial perspective, ICER offers limited value as a budgetary decision-framework to most US insurers who cannot easily translate their final pricing recommendations into coverage. ICER models are US population (vs. specific plan)-based and may differ on key assumptions from the back-of-the-envelope assumptions shown in figure 30. They are not replicable and partly non-transparent and often come with a high degree of uncertainty. As a concept, QALYs are still largely intangible to US payer decision-making and a life-time horizon isn’t useful for actuarial realities and short-term insurance windows in the US (considering frequent beneficiary plan switching).

At the same time, we can report that ICER reviews are widely respected as an “independent” arbiter and a signal on overall product value and is consistently used for background information on the evidence base and specifically for economic data points and key assumptions that enable the economic value story.

Our research shows that an estimated 20% of payers incorporate QALY-based analyses into their price/rebate negotiations with developers for Commercial and Medicare plans.

Figure 31.
Current level of incorporation of clinical comparative effectiveness or QALY-based analyses into formulary decisions/ QA

<table>
<thead>
<tr>
<th>Incorporation of clinical comparative effectiveness</th>
<th>QALY-based analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current level of implementation</strong></td>
<td><strong>Current level of implementation</strong></td>
</tr>
<tr>
<td>Not implemented</td>
<td>Not implemented</td>
</tr>
<tr>
<td>Limited rollout &lt;10% of lives</td>
<td>Limited rollout &lt;10% of lives</td>
</tr>
<tr>
<td>Implemented for 10-30% of lives</td>
<td>Implemented for 10-30% of lives</td>
</tr>
<tr>
<td>Implemented for 40-50% of lives</td>
<td>Implemented for 40-50% of lives</td>
</tr>
<tr>
<td>Implemented for &gt;70% of lives</td>
<td>Implemented for &gt;70% of lives</td>
</tr>
<tr>
<td>Fully implemented, &gt;90% of lives</td>
<td>Fully implemented, &gt;90% of lives</td>
</tr>
</tbody>
</table>

- Average all payers
- PBM
- Large plans
- Mid-sized plans
- Small plans
- IDNs

Commercial (n=31)  Medicare (n=25)
FUTURE EXPECTATION

• 50% of payers report that they are likely to use QALY-based assessments like ICER in decision-making. This contrasts with a higher share at 70% of payers, who are likely to use comparative effectiveness research in formulary decision-making in the next three years. They expect QALY-based, cost-effective analyses to guide formulary inclusion/exclusion for about 30% of lives in both Commercial and Medicare.

• Establishing an official, independent US HTA is payors’ most preferred of all major recent policy proposals. While receiving average level of “somewhat” support, it still ranks roughly 20% in preference above drug Importation and POS rebate pass-through legislation, and even 4% higher than ‘External Pricing Indexing,’ such as introduced by HHS.54 Payers managing 63.7M lives and 73.8M lives strongly favor or somewhat favor having an official cost effectiveness body in the US, respectively.

Figure 32.
Current level of incorporation of clinical comparative effectiveness or QALY-based analyses into formulary decisions/ QA

Figure 33.
Level of payer support for policy proposal to institute an independent US HTA body which appraises drug value through QALY-based cost-effectiveness methods

Level of support for policy to institute an independent US HTA

[Diagram showing level of support for policy to institute an independent US HTA]

Notes: Small payers (<920,000 lives); mid-sized payers (920,000 and <3,400,000 lives); large payers (>3,400,000 lives)

* n=16, representing 136M lives
** n=21, representing 166M lives
DEVELOPER TAKEAWAYS

- While QALY-based approaches like that of “ICER” do not render themselves for easy adoption for payer decision making, they have become an important element in negotiations, and most payers today acknowledge considering such reports at some point during the drug evaluation process.
- Given the opportunity to use utilization management tools as outlined in previous sections, payers are keen to look for assumptions to define eligible patients when considering coverage, limiting PA to label and/or trial, and opportunities for coverage with evidence development and/or outcomes-based deals. Additional collection of clinical evidence may be required for re-authorization when coverage is re-evaluated.
- “ICER” does not currently follow a standardized selection process for its review of therapies. Getting involved with the process during the review window is critical, but engagement doesn’t equate to influence over shaping the report findings. Analyses show that contributions rarely result in major amendments in terms of the conclusion but may significantly influence the revision of model assumptions which may matter to US payers.
- “ICER” generally acknowledges industry comments per table response and tends to address specific methodological considerations with varying levels of robustness. As long as specific alternatives have been offered by the developer, roughly 1/3 of suggestions make their way into final reports, thereby modifying the final evidence report. However, significant variation exists and not all changes are desirable from a developer perspective.
- Developers should explain systematically why they might find specific “ICER” assumptions to be problematic and illustrate the materiality of these concerns towards the value determination more definitively wherever possible (e.g. are these concerns leading to a required shift in value category?). We reiterate that a strong need remains for developers to provide greater specificity and determination in their comments and interaction with ICER.

Figure 34. Targeted publications as part of a strategic ICER defense

<table>
<thead>
<tr>
<th>SITUATION</th>
<th>SOLUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tesaro’s niraparib in ovarian cancer was selected for inclusion in ICER review: ICER findings suggested discount rates of 57-90%</td>
<td>Certara published “Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy” demonstrating the use of niraparib could result in significant cost savings compared with other maintenance treatment options included in the ICER report. Neezer K, O’Neill WM, Stein L, Harrow B, Travers K. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy. Journal of Comparative Effectiveness Research, 2019;8(8):577-597. doi:10.2217/cer-2018-0069</td>
</tr>
<tr>
<td>UCB’s certolizumab pegol was chosen for an ICER’s review in rheumatoid arthritis. Project goal was to contextualize the positive results (“more effective, less costly” versus adalimumab) in a more payer friendly context for market impact (rather than using cost/QALY)</td>
<td>Certara prepared model for publication showing certolizumab pegol treatment associated with lower one-year and two-year costs per low disease activity (cost per response) compared to adalimumab. Chua A, Lee E, Balston P, et al. Cost Per Response of Certolizumab Pegol Versus Adalimumab Among Biologic-Naive Patients With Moderate or Severe Rheumatoid Arthritis: From the US Payer Perspective. Value in Health, 2018;21:194. doi:10.1016/j.jval.2018.04.1321</td>
</tr>
</tbody>
</table>
Innovative Financing for Novel Therapies
The advent of transformative medicines has amplified affordability concerns among payers, providers, and patients. Stakeholders agree that both funding and delivery systems are inadequate to deal with a wave of future cures. Until recently, little had changed in the thinking about how to pay for and deliver these therapeutic innovations.

With respect to gene therapies, different US payer types are variably exposed to three core risks:

- **Actuarial uncertainty** (how many eligible patients will be in our insurance pool?)
- **Therapeutic performance** (how do we assess long-term, real-world effectiveness of treatments?)
- **Payment timing** (how do we administer payment given plan switching and beneficiary migration?)

Health plans conduct individual risk assessments: Broadly speaking, smaller beneficiary numbers result in higher financial exposure on a per-patient cost basis and comparatively greater operational challenges given the need for highly specialized treatment knowledge. Some small commercial payers, self-insured employers, MA Advantage and Medicaid can be expected to see a higher impact than larger commercial payers and Medicare Fee-for-Service. Insurance risks vary further across therapy modalities for the different target populations in question. Payers think that multiple payment solutions are required to mitigate the impact of a proliferation in transformative high-cost therapies—but few concrete mechanisms exist today.

Figure 35.
Range of payment innovations
Case in Point: How to value, how to pay for cures?

- Zolgensma, approved in May 2019, was the first gene therapy to cure young children with spinal muscular atrophy (SMA), a rare genetic disease. While some investigations exposed data manipulations in Zolgensma’s pre-clinical research, the FDA highlighted that human clinical trial data support its efficacy and justify its place in the market. It was priced by Novartis/ AveXis at over $2M for an injection administered once, while the therapy value accrues over a patient’s lifetime. The disconnect between payment and outcomes reveals a fundamental challenge to the current ‘pay-as-you-go’ funding approach.
- The lifetime savings potential is exceptional in terms of reducing the burden of mortality, disability and overall treatment costs. But collapsing decades worth of potential cost-offsets into the single, one-time administration produces extraordinary upfront budget pressure on payers.
- The cumulative effect of curative therapies across multiple conditions is likely going to put increasing strain on the current structure. Another compounding challenge for health systems’ value determination here is the lack of long-term durability data at launch, a performance outcome measure that the clinical trial research can’t capture. In view of the evidence, are we right to assess these therapies under the same criteria we established decades ago to manage the much more predictable cost of chronic conditions? In the case of Zolgensma, “ICER” estimated a value-based price to be between $1.2M and up to $2.1M (assuming an alternative thresholds of $100,000 to $150,000 per life year gained). But once we move beyond the hurdle of defining a value-based price to the question of paying for these cures, a corresponding set of alternative reimbursement models, so-called ‘precision financing’ schemes for precision cures, is required to assure affordability and reimbursement.

Milestone-based Outcomes Contracts for Payment Innovation

- Performance-based contracts involve an upfront payment and reception of refunds over either the short-term (<1 year) or long-term (e.g. five years) and can help to reduce the risk around a variability in response and to limit treatment costs.
- Developers may rebate based on nonresponse rates in individual patients, pay a discount based on performance within a population, or pay for additional treatment costs associated with suboptimal responses to therapy. Common deal parameters include (a) the adjustments of an additional rebate (above a base rebate) proportionate to pre-defined outcomes metrics; (b) financial guarantees to pay for plan beneficiaries who missed an outcomes performance threshold (e.g., cost for impacted members pharmacy spend related to the product, total pharmacy costs of all utilized products relating to the condition, hospitalization costs, also for all patients on product if population-level); or c) total cost-of-care guarantees for patients on the manufacturer’s product (e.g., on a per episode-basis or population-based per member per month) with applied outcomes data to adjust for the negotiated risk share of either payout (shortfall of the guarantee) or shared savings (in excess of guarantee).

Figure 36. Simplified modalities of milestone-based outcomes contracts across the short-term (1 year), and multi-year horizon
Different types of outcomes-based agreements (OBAs), such as with adjustments on individual or population-based outcomes metrics, are currently used in less than 10% of covered lives, as perceived by respondents in this survey. As Certara has documented in a series of OBA whitepapers over the past three years, the recent rise of risk-sharing agreements in the US is clear evidence that outcomes-based contracting has become a reality in the marketplace, but we should stress that it is neither the norm nor the panacea for a majority of pharmaceutical reimbursement.

We also note that only 1 in 3 surveyed MCOs with OBA experience today is satisfied with the agreements they have seen put in place by their organization. 35% of payer respondents currently have, or have had, an OBA (see figure below). All of these payers note that they have obtained value for money and have renewed, or will seek to renew these OBAs and similar types in the future. Figure 37.

Payers who have past or current experience with outcomes-based contracts

Figure 38.
Challenges with the implementation of value-based agreements

Stakeholder-cited challenges with OBA implementation

- Assessing risk upfront due to uncertainties around real world performance.
- Managing lack of control (over outcome, proper dosing, product use, adherence...).
- Finding adequate time horizons in fragmented, multi-payer insurance market.
- Managing resource requirements to set up and adjudicate compared to traditional rebates and discounts.
- Leveraging data infrastructure adequately for measuring/monitoring relevant outcomes.
- Reaching contractual agreements b/w all stakeholders.
- Managing risk of potentially burdening physicians with uncompensated data collection.
FUTURE EXPECTATIONS

- When asked about their likelihood for renewal, contracts are expected to be renewed for national plans. Only IDNs are moderately confident to expand OBA use beyond pilots.

- Additional qualitative feedback also indicates why the current types of OBA have seen limited scale, frequently citing lack of resources and lack of manufacturer’ commitment to more meaningful areas of implementation. Developers also must agree to a set of measurable and obtainable outcomes which can be challenging in several disease states.

- Given the need for third-party adjudication services, and data and analytics infrastructure to track patients over time (across payers and providers), we do not expect a large-scale uptake within the next three years. These steps add to the already costly administration and legal complexity. At the same time, developers are well advised to be prepared for the emerging payer environment where meaningful commitment to value in the real world, not RCT simply results, will be the marker of differentiation.
Following our results, there is still an opening for developers to further adopt alternative models – but it remains restricted to IDN archetypal within the next three years.

We believe that regulatory clarity would serve as a key enabler: CMS could provide reasonable accommodation for best-price and other government price reporting, the OIG could advance anti-kickback statues to define explicit safe harbors, and FDA could further specify communication guidelines to enable appropriate communication between payers and developers. There have been encouraging proposals by the OIG and CMS for new AKS and Stark protections for value-based agreements on the provider site currently pending at OMB, but such arrangements explicitly exclude manufacturers of drugs, medical equipment, prosthetics, orthotics or supplies.

Figure 40.
Outcomes based agreement with financial adjustment based on performance in population (Commercial)

Figure 41.
Outcomes based agreement with financial adjustment based on performance in individual patients (Commercial)

Figure 42.
Outcomes based agreement with financial adjustment based on performance in individual patients (Commercial)
Annuities Payments/ installment Financing

- The objective of annuity financing (which can be combined with outcomes measures) is to spread the cost of a therapy over a fixed time frame thus smoothing the scheduling of payments. This would help tackle the immediate budget pressures in the first year faced by smaller insurance pools and partially mitigate the actuarial risk around patient backlogs and individual high-cost cases. Typically, the timeframe is based on the durability of response in the trial; many payers would want to see five years. This currently faces a major implementation obstacle in terms of patient potability.

CURRENT STATE

- Currently, no payers report using annuity financing arrangements. Policymakers have hitherto made no tangible commitment to developing an infrastructure for annuity financing or to enabling long-term, value-based pharmaceutical reimbursement.

FUTURE EXPECTATIONS

- We note that the bi-partisan legislation from the Senate Finance Committee (Grassley/Widen) would enable Medicaid plans to amortize the cost of delivering curative gene therapy over time.

- Given the multi-year contract horizon, open questions around patient tracking, pricing regulation and accounting issues persist and payer interest in adopting these payment options is muted.

Figure 43.
Simplified modalities for multi-year installment payments

Figure 44.
Interest in adopting annuity payment model within the next 3 years (Commercial)

Adopt annuity financing model within 3 years

- Not at all likely (1)
- Unlikely (2)
- Medium (2.3)
- Likely (3)
- Somewhat likely (4)
- Somewhat unlikely (5)
- Extremely unlikely (6)

All payers (2.5)
(n=31)
Reinsurance / Stop loss

CURRENT STATE

• Reinsurance (e.g. purchased by payers) and stop loss insurance (e.g. purchased by self-funded employer organizations) is currently employed to manage the actuarial risk of single plan-year contracts. For example, payers pay the third-party insurer per member per month (PMPM) to assume the risk for unexpected events above a certain cost threshold.

Figure 45.

Payers’ current level of implementing re-insurance and stop loss insurance

FUTURE EXPECTATIONS

• Applied to the context of transformative therapies, the reinsurance/stop loss approach could work well in incident populations but faces challenges in multi-year agreements since high-cost claimants will have to be disclosed to re-insurers and are often “lasered out” of future policies which focus specifically on insuring unknown and unexpected financial risk.

• We observe that interest in growing annuity models is fairly significant among commercial payers at “somewhat likely” with IDNs and Midsized payers most interested and PBMs being “rather unlikely” to implement within the next three years.

Figure 46.

Interest in reinsurance/ stop loss models (Commercial) within the next 3 years
Subscription-based Pricing

**CURRENT STATE**

- Following the principle of a subscription, the approach also called the “Netflix model” aims at ensuring patient access to a therapy for a given population at a predictable cost. In 2019 Medicaid state payers Louisiana and Washington decided to reimburse the manufacturers Gilead and AbbVie, respectively, based on fixed amounts for multi-year-periods for HCV drugs.
- Currently, no payers have implemented subscription-based pricing across Commercial or Medicare lives.

**FUTURE EXPECTATIONS**

- The set-up of the governing contract follows a public ‘winner takes all’ auction in which the lowest bidder earns the right to supply product for the agreed-on license. In the two US cases, the auction seems to have resembled more of a confidential negotiation process led by the state payers with each of the three competing bidders. Price tenders remain unpublished, but our researched estimates of the accepted agreements in the US are provided in figure 47.
- Subscription licensing models fall in line with alternative approaches that de-link innovation from unit pricing, following the rationale that any additionally treated patient does not represent a higher cost to payers who, in turn, would avoid limiting access restrictions otherwise necessary to protect their budgets.
- Going forward, only 13% of payers\(^a\), are somewhat interested in adopting subscription-based pricing models for Commercial plans.
- There is little interest of implementing such a financing model on the Medicare side with only 2 respondents somewhat likely to explore this financing option for Medicare plans.
- In Medicaid, the states of Oklahoma, Michigan and Colorado reported to have evaluated this approach.

---

**Figure 47. Current subscription model in the US market (Medicaid)**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Awarded manufacturer</strong></td>
<td>Asegua (Gilead subsidiary)</td>
<td>AbbVie</td>
</tr>
<tr>
<td><strong>Bidders</strong></td>
<td>3 – AbbVie, Gilead, Merck</td>
<td>3 – AbbVie, Gilead, Merck</td>
</tr>
<tr>
<td><strong>Lump sum amount total</strong></td>
<td>$290M – potential</td>
<td>$321M – contracted</td>
</tr>
<tr>
<td><strong>Payment modality</strong></td>
<td>Up to $58M per year</td>
<td>Upfront</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>5 years contracted</td>
<td>4 years, 2-year extension option</td>
</tr>
<tr>
<td><strong>Patients targeted</strong></td>
<td>31,000 (2024) / 10,000 (2020)</td>
<td>30,000 (2023)</td>
</tr>
<tr>
<td><strong>Price per patient targeted</strong></td>
<td>$9,354</td>
<td>$10,700</td>
</tr>
<tr>
<td><strong>2018 Medicaid price</strong></td>
<td>$24,363</td>
<td>$24,363</td>
</tr>
<tr>
<td><strong>Expected discount over best price</strong></td>
<td>61%</td>
<td>56%</td>
</tr>
<tr>
<td><strong>Additional details</strong></td>
<td>Modified licensing – fixed/ unit price until cap, unlimited pricing thereafter</td>
<td>AbbVie commits to patient identification, outreach, diagnosis</td>
</tr>
</tbody>
</table>

\(^a\) n=4, representing 52M Commercial lives
Implications for Developers

- Despite heightened excitement around innovative financing models, MCOs in the US see comparatively little to no current use. Thus, we see few immediate opportunities for the adoption among private insurers. This is partially due to beneficiary switching at the end of the plan year that doesn’t allow for the continuity in the treatment population that the approaches require while unit-level reporting requirements are legal and administrative barriers.

- Propositions such as licensing models have unquestionable public health value as long as no further treatment innovation is to be expected in the category. By nature, this limits the model to indications and categories where continued R&D can be sacrificed for budget surety such as curative therapies.

- While some tactical benefits may sound appealing to manufacturers at first sight — e.g. annual recurring revenue and cashflow certainty, reduced COGS etc — the shift may be indicated for a limited set of competitive scenarios, e.g. for a hold on a patient pool that is diminishing when competitive differentiation is unable to open the funnel. As figure 48 shows in a simple simulation, properly accounting for the potential loss of the entire segment as a result of the auction or bidding process limits the commercial rationale of pushing for licensing models in most scenarios.

Figure 48.
Simplified scenario for licensing options and revenue risk: Not always “win-win”

- Under any circumstance, developers need to make sure to have a superior understanding of the prevalence within the state population and gauge the price-volume accordingly. If the increase in volume reduces a defined contribution margin (driving up COGS) at a decreasing net price and the resulting decline in profitability for the entire market appears to be greater than forgoing sales in that state’s Medicaid segment, they should re-consider. If they proceed, they must define what share of the delta they can claim to take home given the product’s value delivered to the entire patient population.

- For any non-traditional pricing agreement, successful developers are supported by a multi-disciplinary pricing steering committee and have provisioned for monitoring and adjudication systems.

<table>
<thead>
<tr>
<th>Unit-based sales (conventional model)</th>
<th>Subscription model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment cost: $30,000/patient</td>
<td>Lump sum: $190M</td>
</tr>
<tr>
<td>Annual patient pool for condition: 8,000</td>
<td>Annual patient pool: 14,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Market scenario 1</th>
<th>Product A: 40%</th>
<th>Product B: 40%</th>
<th>Product C: 20%</th>
</tr>
</thead>
<tbody>
<tr>
<td>New TRx starts</td>
<td>(3,200 pts)</td>
<td>(3,200 pts)</td>
<td>(1,600 pts)</td>
</tr>
<tr>
<td>Expected revenues (conventional model)</td>
<td>$96M</td>
<td>$96M</td>
<td>$48M</td>
</tr>
<tr>
<td>Likely subscription revenue</td>
<td>$57M</td>
<td>$57M</td>
<td>$57M</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Market scenario 2</th>
<th>Product D: 66%</th>
<th>Product E: 17%</th>
<th>Product F: 17%</th>
</tr>
</thead>
<tbody>
<tr>
<td>New TRx starts</td>
<td>(5,280 pts)</td>
<td>(1,360 pts)</td>
<td>(1,360 pts)</td>
</tr>
<tr>
<td>Expected revenues (conventional model)</td>
<td>$158M</td>
<td>$40.8M</td>
<td>$40.8M</td>
</tr>
<tr>
<td>Likely subscription revenue</td>
<td>$57M</td>
<td>$57M</td>
<td>$57M</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Market scenario 3</th>
<th>Product G: 50%</th>
<th>Product H: 20%</th>
<th>Product I: 15%</th>
<th>Product J: 35%</th>
</tr>
</thead>
<tbody>
<tr>
<td>New TRx starts</td>
<td>(2,400 pts)</td>
<td>(1,600 pts)</td>
<td>(1,200 pts)</td>
<td>(2,800 pts)</td>
</tr>
<tr>
<td>Expected revenues (conventional model)</td>
<td>$72M</td>
<td>$47.5M</td>
<td>$26M</td>
<td>$47.5M</td>
</tr>
<tr>
<td>Likely subscription revenue</td>
<td>$47.5M</td>
<td>$47.5M</td>
<td>$47.5M</td>
<td>$47.5M</td>
</tr>
</tbody>
</table>

In this simplified Medicaid example, we are assuming a state payer wants to see net savings of $50M on its annual expenditures for the category, but in turn expect a 75% demand surge given the removal of utilization restrictions limiting patient access under current pricing. The assumption seem reasonable looking at conceptual and recently discussed models in Louisiana and Washington.

Given that the bidding process is not public, manufacturers cannot pre-determine their success in the process — even though revenues under the lump sum would be guaranteed, the risk is significant as only one market participant will be rewarded.

For the 10 firms in our simulation, only those with products with a preference share of less than 20% fare better under the subscription model if we apply a probability-weighted revenue forecast. In 60% of the situations, the traditional unit sales provide higher expected revenues, with a significantly higher overall revenue in each case.
Emergence of Novel Entities to Manage Orphan Benefits?

A few collaborative efforts have lately put the development of so-called ‘precision financing’ schemes for precision cures on the public policy agenda. One of the more prominent multi-stakeholder initiatives in the US was launched at the Massachusetts Institute of Technology (MIT). Their Financing and Reimbursement of Cures (FoCUS) project has recently presented a set of alternative reimbursement models based on “Design Lab” workshops, primary research, financial modeling and case study analyses.

The aim is to advance a practical toolkit that helps drive early adoption and enables payers to guarantee patient access to novel therapies. For the future state of transformative therapy commercialization, the colleagues at MIT imagine the possible emergence of novel provider-administrator entities to support and administer novel financing models. These intermediaries, so-called Gene Therapy Administrators or Orphan Reinsurer and Benefits Managers (ORBM), could combine the risk-bearing of reinsurers with the therapy contracting capabilities of PBMs, and the provider network building, and medical management capabilities of insurers (Figure 50).

While no such dedicated vendor exists today, third parties are already providing these services. Additional capabilities such as specialty pharmacy distribution could hypothetically, be added as well. Below is an overview presented by the MIT initiative as a first step of conceptualizing the promise of an inter-mediating entity. However, the specific confines of the business model behind the ORBM are yet to be fully fleshed out.

Conceptualizing the new entity of the Orphan Benefit Manager (proposed by Trustheim et al, 2018)
A critical question for the future of innovative contracting is whether any of the negotiated financial benefits between manufacturer and payer will ever reach the patients and how can we operationalize that.

— MAXIMILIAN VARGAS, Sr. Director, Certara
Figure 52.
Barriers to adoption of novel financing arrangements, and innovative horizons to overcome them

Major questions for innovative payment arrangements

- Patient portability?
- Administrative program complexity?
- Information burden for tracking?
- Pricing and reporting regulations prohibitive?
- Insurance regulatory barriers?

Innovation to overcome implementation barriers on the horizon

Horizon 1: Pilots within the status quo
- e.g. CMS informal discussions, formal guidance, demonstration waiver, CMMI models, Medicaid state plan amendments (suppl. rebates)

Horizon 2: Partnerships beyond exiting structures
- Regulatory transformation

Horizon 3: Unleashing enablement via novel legal paradigm
- e.g. OIG AKS guidance, Safe Harbor protections, federal legislative blueprints to remove systemic barriers, e.g. Grassley-Wyden to enable Medicaid value-based pricing models (and congressional amendments)

Evolving reimbursement through collaborative frameworks
- e.g. PBMs as gene therapy distributors, federal/ state re-insurance risk pools, consortia and annuity funds, mutual recognition strategies across payers, CoE led patient registries...

Working through existing reimbursement system

Degree of change

Expected window of returns

Expected time to implementation
Escalating Policy Environment
Legislative context

- In the 2020 campaign for the US White House, the pharmaceutical industry had become a prime target of bipartisan outrage. We should note that the healthcare debate’s focus on drug costs and pricing processes is not new – it has been a matter of public debate for over thirty years. The recent inflation of regulatory rule-making in Washington and the degree of disruption likely to be caused by key legislative proposals, are seen by many as historically unprecedented.

- With the so-called “Blueprint”, the Trump Administration released an aggressive set of drug pricing reform concepts in May 2018 aiming to combine volume control with limitations on branded drug spending followed by rule-making activity at unforeseen levels.

- Several regulatory proposals are still under debate, and some have been withdrawn following public comment periods. By many accounts, one of the most disruptive and the furthest progressed towards becoming law is the International Pricing Index Proposal (IPI) that seeks to peg Part B prices on averaged Ex-US prices. It is currently pending under OMB. Listen to our our 2018 analysis here: https://tinyurl.com/ybwy2d32.

“
In recent years, health policy pushes have seen an increasingly nuclear focus on drug costs and pricing processes. We are witnessing regulatory moves at unforeseen speed towards combining volume control with regulations on pharmacy costs on the federal level. At the same time there is an escalation in various state legislatures to regulate drug pricing transparency, co-pay assistance, importation, rate setting, price gouging, spending targets, group purchasing and biosimilar substitution.

– ULRICH NEUMANN, Sr. Director, Certara

Passed regulations

- Final rule-making with respect to Medicare Part B:
  - Allowing Medicare Advantage plans to use step therapy for physician-administered drugs.
  - Payment reduction for drugs purchased with 340B discount to ASP-22.5%.
  - Changes to new drug reimbursement (prior to ASP data availability) to 1035 of WAC (with sequestration cuts, effectively WAC +1.35%).

- Final rule-making with respect to Medicare Part D:
  - Plans given broader flexibility to make formulary maintenance changes mid-year immediately upon generic approval.
  - Announcement of the voluntary “Senior Savings Model”, offering alternative Part D options with OOP cost caps for a set of plan-formulary insulins at $35/30-day supply for both standalone PDPs and Medicare Advantage (MA-PD) with beginning CY 2021 participating developers Lilly, Novo Nordisk and Sanofi.
Major congressional legislation

• Key piece of legislation passed in the House of Representatives is H.R.3, the “Lower Drug Costs Now Act”, combining various measures in three main categories: inflation-based rebates, caps on patient out-of-pocket spending and direct price negotiations. The latter would be run by the federal government but grants access to prices to all commercial plans, applied to at least 25 and at most 250 drugs, leveraging tax penalties for developers who refuse to come to accept agreements within 2 months which can range to from 65% and up to 95% of sales proceeds. Estimates suggest the bill would reduce net revenues of developers by up to $1 trillion or roughly 58% of companies’ earnings before interest and taxes (EBIT), and the non-partisan Congressional Budget Office predicted that $456bn savings to the government over 10 years may come with the effect of 30 fewer novel drugs coming to market given reduced innovation incentives. Other health economic studies indicate that the impact on small and emerging biotech could be more dramatic resulting in small biotech in states like California developing 88% fewer drugs.

• A major bill under discussion in the Senate is the bi-partisan legislation passed within the Senate Financing Committee. The “Prescription Drug Pricing Reduction Act” by Senators Grassley and Widen is drawing on inflation caps and benefit re-designs aiming to reduce government spending on drugs by $100 billion across Medicare and Medicaid programs over the next decade. The bill received support from the White House but at the time of publication of this report has yet to be brought to a Senate floor vote by Senate Majority Leader McConnell.

• If we dissect the major drug pricing reform bills that are currently debated in both houses of Congress and under consideration for rule making by HHS, we find a cluster of core policies suggestions:
  • Government Drug Price Negotiation (e.g. in H.R. 3),
  • Importation of Products (proposed by HHS in Dec. 2019, such as from Canada),
  • Pass-Through of Rebates (to Point-of Sale, e.g. HHS proposal in 2019),
  • External Reference Pricing (i.e. adjusted by international price basket of selected countries, proposed as the HHS IPI Model for Part B),
  • Internal Reference Pricing (i.e. adjusted with a price basket of similar therapeutics, a called pre-specified equivalence class).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Beneficiaries</td>
<td>25% co-insurance in initial coverage limit $2,000 OOP cap</td>
<td>15% in initial coverage limit $3,100 OOP cap</td>
</tr>
<tr>
<td></td>
<td>Beneficiaries that would exceed OOP cap with first fill of year would have option to amortize payments across remainder of plan year</td>
<td></td>
</tr>
<tr>
<td>Plan sponsors</td>
<td>50% in Catastrophic</td>
<td>60% in Catastrophic</td>
</tr>
<tr>
<td>Manufacturers</td>
<td>10% in initial Coverage Limit 30% in Catastrophic</td>
<td>10% throughout benefit 7% in initial Coverage Limit 14% in Catastrophic</td>
</tr>
<tr>
<td>Medicare</td>
<td>20% in Catastrophic</td>
<td>20% in Catastrophic 30% in Catastrophic for multiple-source drugs</td>
</tr>
<tr>
<td>Estimated savings (10 year)</td>
<td>$90 Billion</td>
<td>No CBO score yet</td>
</tr>
</tbody>
</table>

Figure 53. Key legislative proposals impact on Part D re-design
Policy Dashboards: Positioning payers on drug pricing proposals

- Figure 53 shows the overall level of support of key payer archetypes for the core reform policies. PBMs tend to be least enthusiastic about current price reform proposals being on average “neutral” across all policies. With the exception of large plans which fall in slightly opposing territory on government price controls, we must note that at least, on average, no other payers are opposed or strongly opposed to any of the legislative proposal though.

- Internal reference pricing and drug importation are most supported by midsized plans. Small plan representatives lead support on international price referencing, while IDNs lead support across all other policy categories. Except for internal reference pricing which receives strong marks from mid-size plan representatives, looking across the mean the level of support is in broad summary not enthusiastic but still mildly in favor.

![Figure 54. Average level of support for legislative proposals around drug pricing](chart)

- Given the potentially drastic consequences of these proposals on pharmaceutical spending and innovation as well as the very nature of payer-pharma engagements, we decided to present six panels with a closer look on various payer types. These deep dives reveal the level of support for the current proposals within archetypes as well as the noticeable range of opinions among their individual payer representatives. While we underscore that these results are qualitative in nature and not a representative survey of the US payer universe, they offer unique insights into the considerable support that exists among so many commercial insurers, responsible for millions of US lives, for a set of policies that are historically antithetical to the free market-based drug pricing paradigm that distinguished the US from the rest of the world for many decades. We believe that a shift in political and public opinion has made its mark on payer sentiments; a trend our research will closely document in future editions of this report.

- Overall, most payers are in favor of drug pricing proposals—with IDNs and midsized/medium plans the most supportive and PBMs the least supportive. Proposals around internal reference pricing and international pricing indexing draw the most support across all payer archetypes.
• Overall, there is most PBM support for legislation around internal reference pricing with strong or somewhat favorable support from 4 PBM representatives responsible for 21.9M US lives. Outside of this, strong support is only seen by 1 PBM respondent responsible for 34M covered lives around international pricing indexing legislation.

• Overall, legislations around internal reference pricing has the strongest support from IDN payer respondents with five respondents responsible for 18.4M total lives somewhat or strongly in favor. Government price negotiations is the second most supported legislation by IDNs (n=4) representing 12.1M lives.

\textsuperscript{ee} n=7; 59.9M lives   \textsuperscript{ff} n=6; 24.4M lives
Large plans representing 121.6M lives support international pricing indexing. The second most supported pricing proposal across large plans by those responsible for 115.9M lives are around internal reference pricing.

Across mid-sized plans, the most supported legislative proposal is for internal reference pricing favored by plans representing 10M lives. International Pricing Indexing is the second most supported proposal across plans responsible for 9.5M lives.

Figure 57. Average level of support for legislative proposals concerning drug pricing for Large plans

Figure 58. Average level of support for legislative proposals concerning drug pricing for Medium/mid-sized plans

\[ n=16, \ 182M \ lives \]  
\[ n=8; \ 13.5M \ lives \]
Almost all respondents of small plans, responsible for 3.0M lives, are in favor of international pricing indexing pricing. Proposals around internal reference pricing is the next most supported among respondents representing 2.8M lives.

**MANUFACTURER TAKEAWAYS**

- Some proposals discussed here are in the rule-making stage, others supported by individual states and some by the US House of Representatives and the Senate Minority. The 2020 elections will determine how some of the proposals will fare in the near-term future. Most entail relatively drastic consequences on the nature of the relationship and negotiations between innovators and payers.

- Except for large plans, payer representatives on average do not oppose government price setting or drug importation. Moreover, payer representatives responsible for over $150M favor drug importation and international price indexing.

- Manufacturers need to monitor payer sentiment carefully. While payers in our survey would not implement individual policy proposals except for internal reference pricing, their views represent a critical expression on the dissatisfaction with current price-setting mechanisms in the specialty category. Substantial support has evolved for a set of historically antithetical policies to the free, market-based US pricing system. We expect these pressures to further escalate and would highlight that applying historic probabilities to the likelihood of such proposals advancing in the legislative path may result in a false sense of comfort.

- In view of the intensifying public sentiment against the current drug pricing system, bipartisan groups in the Congress and contenders for the White House are more unafraid than ever to demonstrate their legislative resolve. The election of a Biden administration may postpone CMS action to 2021, but the policy priorities in both parties are unlikely to shift the direction of travel.


45 EMD Serono Specialty Digest: Managed Care Strategies For Specialty Pharmaceuticals. 14th ed. EMD Serono; 2018.


53 Pharma Exec Trends.


About Certara

At Certara, we accelerate medicines to patients, partnering with life science innovators. Together with our partners, we use biosimulation and technology-enabled services to transform drug discovery and development.

For more information visit www.certara.com or email sales@certara.com.